JPH06502410A - 二特異的試薬を用いた標的免疫化 - Google Patents
二特異的試薬を用いた標的免疫化Info
- Publication number
- JPH06502410A JPH06502410A JP3518279A JP51827991A JPH06502410A JP H06502410 A JPH06502410 A JP H06502410A JP 3518279 A JP3518279 A JP 3518279A JP 51827991 A JP51827991 A JP 51827991A JP H06502410 A JPH06502410 A JP H06502410A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- receptor
- antibody
- molecular complex
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title description 3
- 230000003053 immunization Effects 0.000 title description 2
- 238000002649 immunization Methods 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims description 113
- 108091007433 antigens Proteins 0.000 claims description 113
- 102000036639 antigens Human genes 0.000 claims description 113
- 102000005962 receptors Human genes 0.000 claims description 38
- 108020003175 receptors Proteins 0.000 claims description 38
- 239000011230 binding agent Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 33
- 229940027941 immunoglobulin g Drugs 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 27
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 25
- 108010087819 Fc receptors Proteins 0.000 claims description 19
- 102000009109 Fc receptors Human genes 0.000 claims description 19
- 210000002540 macrophage Anatomy 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 208000006454 hepatitis Diseases 0.000 claims description 9
- 231100000283 hepatitis Toxicity 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (36)
- 1.抗原提示細胞の表面レセブタのための天然リガンドによって実質的にブロッ クされることなく該表面レセプタに結合する結合剤と、抗原とを投与し、その結 果として該抗原を該レセプタに向かわせることを含む、抗原に対する免疫応答を 刺激する方法。
- 2.該抗原を該結合剤にカップリングさせる請求の範囲第1項の方法。
- 3.該結合剤が抗体もしくはそれのフラグメントである請求の範囲第2項の方法 。
- 4.該結合剤が二特異性を示し、該レセプタに対して結合親和性を示すと共に該 抗原に対して結合親和性を示す請求の範囲第1項の方法。
- 5.該抗原と該二特異的結合剤を複合体として投与する請求の範囲第4項の方法 。
- 6.該二特異的結合剤が異種抗体である請求の範囲第4項の方法。
- 7.該抗原が、ウイルス、細菌、寄生虫および腫瘍関連抗原から成る群から選択 される請求の範囲第1項の方法。
- 8.該抗原が肝炎ウイルスから誘導される請求の範囲第1項の方法。
- 9.該肝炎抗原が肝炎表面抗原である請求の範囲第1項の方法。
- 10.該抗原がHIV抗原である請求の範囲第1項の方法。
- 11.該抗原提示細胞がマクロファージである請求の範囲第1項の方法。
- 12.該マクロファージの表面レセプタが免疫グロブリンFcのためのレセプタ である請求の範囲第1項の方法。
- 13.該免疫グロブリンFcのためのレセプタが免疫グロブリンGのための高親 和性Fcレセプタである請求の範囲第12項の方法。
- 14.免疫グロブリンG(IgG)によって実質的にブロックされることなくマ クロファージ表面上のIgGのためのFcレセプタに特異的に結合する第一抗体 もしくはそれのフラグメント、および特異的に抗原に結合する第二抗体もしくは それのフラグメントを含んでなる二特異的異種抗体と抗原とを含んでなる分子複 合体を投与することを含む、抗原に対する免疫応答を刺激する方法。
- 15.該二特異的抗体がFabxFab接合体を含んでいる請求の範囲第14項 の方法。
- 16.第一Fabが、IgGによって実質的にブロックされることなく免疫グロ ブリンGのための高親和性Fcレセプタに結合し、そして第二Fabが抗原に結 合する、FabxFab異種抗体とB型肝炎表面抗原もしくはそれの一部を含ん でなる分子複合体を、ウイルスに感染した個体に投与することを含む、B型肝炎 感染を治療する方法。
- 17.レセプタのための天然リガンドによって実質的にブロックされることなく 抗原提示細胞に結合する結合剤にカップリングさせた抗原の複合体を投与するこ とを含む、抗原に対する免疫応答を刺激する方法。
- 18.該マクロファージの表面レセブタが免疫グロブリンFcのためのレセプタ である請求の範囲第17項の方法。
- 19.抗原提示細胞の表面レセプタのための天然リガンドによって実質的にブロ ックされることなく該レセプタに結合すると共に抗原に結合する二特異的結合剤 との複合体を形成している抗原を含んでなる分子複合体。
- 20.該二特異的結合剤が異種抗体である請求の範囲第19項の分子複合体。
- 21.該異種抗体が、化学的に架橋させたFabまたはFab′抗体フラグメン トを含んでなる請求の範囲第20項の分子複合体。
- 22.該抗原が、ウイルス、細菌、寄生虫および腫瘍関連抗原から成る群から選 択される請求の範囲第19項の分子複合体。
- 23.該抗原が肝炎抗原である請求の範囲第19項の分子複合体。
- 24.該抗原がHIV抗原である請求の範囲第19項の分子複合体。
- 25.該抗原提示細胞がマクロファージである請求の範囲第19項の分子複合体 。
- 26.該マクロファージの表面構成要素が免疫グロブリンFcのためのレセプタ である請求の範囲第25項の分子複合体。
- 27.該免疫グロブリンFcのためのレセプタが免疫グロブリンGのための高親 和性Fcレセブタである請求の範囲第26項の分子複合体。
- 28.免疫グロブリンG(IgG)によって実質的にブロックされることなくマ クロファージ表面上のIgGのためのFcレセブタに特異的に結合する第一抗体 もしくはそれのフラグメント、および特異的に抗原に結合する第二抗体もしくは それのフラグメントを含んでなる二特異的異種抗体と抗原とを含んでなる分子複 合体。
- 29.該第一抗体もしくはそれのフラグメントがIgGのための高親和性Fcレ セプタに結合する請求の範囲第28項の分子複合体。
- 30.該抗原が、ウイルス、細菌、寄生虫および病気関連抗原から成る群から選 択される請求の範囲第28項の分子複合体。
- 31.該抗原が肝炎抗原である請求の範囲第28項の分子複合体。
- 32.該肝炎抗原が肝炎表面抗原である請求の範囲第25項の分子複合体。
- 33.該抗原がHIV抗原である請求の範囲第26項の分子複合体。
- 34.第一Fabが、免疫グロブリンG(IgG)によってブロックされること なくIgGのための高親和性Fcレセプタに結合し、そして第二Fabが抗原に 結合する、FabxFab異種抗体と抗原とを含んでなる分子複合体。
- 35.薬学的に許容される賦形剤中に請求の範囲第19項の分子複合体が含んで なるワクチン組成物。
- 36.IgGFcによってブロックされることなく抗原提示細胞のFcγレセプ タに結合する、抗体、フラグメントまたはそれの類似物に連結させた抗原。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59308390A | 1990-10-05 | 1990-10-05 | |
US593,083 | 1990-10-05 | ||
PCT/US1991/007283 WO1992005793A1 (en) | 1990-10-05 | 1991-10-04 | Targeted immunostimulation with bispecific reagents |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06502410A true JPH06502410A (ja) | 1994-03-17 |
JP3583420B2 JP3583420B2 (ja) | 2004-11-04 |
Family
ID=24373308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51827991A Expired - Fee Related JP3583420B2 (ja) | 1990-10-05 | 1991-10-04 | 二特異的試薬を用いた標的免疫化 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0553244B8 (ja) |
JP (1) | JP3583420B2 (ja) |
AT (1) | ATE175118T1 (ja) |
AU (1) | AU667460B2 (ja) |
CA (1) | CA2093022C (ja) |
DE (1) | DE69130709T3 (ja) |
DK (1) | DK0553244T4 (ja) |
ES (1) | ES2129029T5 (ja) |
GR (1) | GR3029830T3 (ja) |
WO (1) | WO1992005793A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002502802A (ja) * | 1997-12-02 | 2002-01-29 | ニューララブ リミテッド | アミロイド形成疾患の予防および処置 |
Families Citing this family (264)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018031A (en) * | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
AU5322494A (en) * | 1992-10-02 | 1994-04-26 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
WO1995024220A1 (en) * | 1994-03-07 | 1995-09-14 | Medarex, Inc. | Bispecific molecules having clinical utilities |
US6111166A (en) * | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
ES2309992T3 (es) | 1995-10-20 | 2008-12-16 | University Of Nebraska Board Of Regents | Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno. |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
EP0808897A1 (en) * | 1996-05-21 | 1997-11-26 | I.D.M. Immuno-Designed Molecules | New antigen presenting cells, a process for preparing the same and their use as cellular vaccines |
US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
AUPO280796A0 (en) * | 1996-10-07 | 1996-10-31 | Austin Research Institute, The | Methods of activating or enhancing FC receptors |
US6737057B1 (en) * | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
WO1999028349A2 (en) * | 1997-12-02 | 1999-06-10 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
WO1999047538A1 (en) | 1998-03-19 | 1999-09-23 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
CA2320491A1 (en) * | 1998-03-30 | 1999-10-07 | I.D.M. Immuno-Designed Molecules | Stimulated monocyte derived cells, their preparation and uses |
US20020168347A1 (en) * | 1998-04-09 | 2002-11-14 | Jacques Bartholeyns | Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency |
DE19835633C1 (de) * | 1998-08-06 | 1999-08-26 | Gsf Forschungszentrum Umwelt | Induktion einer Tumorimmunität durch Redirektion von Tumorzellen gegen Antigen-präsentierende Zellen |
JP2002537769A (ja) | 1999-02-26 | 2002-11-12 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ヒトエンドカインαおよび使用方法 |
EP1173485A1 (en) * | 1999-05-03 | 2002-01-23 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
US20040001826A1 (en) | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
JP2003532687A (ja) | 2000-05-11 | 2003-11-05 | アルタレックス コーポレイション | 抗原−抗体複合体化および樹状細胞による提示を利用する治療法および組成物 |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
EP2027874B1 (en) | 2000-11-28 | 2013-10-16 | Medimmune, Inc. | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20030059834A1 (en) * | 2001-02-01 | 2003-03-27 | Chang Nancy T. | Methods to generate and identify monoclonal antibodies to a large number of human antigens |
EP1683865A3 (en) | 2001-02-02 | 2006-10-25 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
AU2002250032B2 (en) | 2001-02-09 | 2008-06-05 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
EP2228389B1 (en) | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
EP1381384B1 (en) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
JP4376629B2 (ja) | 2002-01-08 | 2009-12-02 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法 |
US20040052773A1 (en) * | 2002-01-18 | 2004-03-18 | Inovio As | Production of multi-chain protein from muscle |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2005535572A (ja) | 2002-04-12 | 2005-11-24 | メディミューン,インコーポレーテッド | 組換え抗インターロイキン−9抗体 |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US7425619B2 (en) | 2002-08-14 | 2008-09-16 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
ES2347959T3 (es) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer. |
AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
PT1703893E (pt) | 2003-12-23 | 2012-06-01 | Genentech Inc | Novos anticorpos anti-il 13 e as respectivas utilizações |
HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
JP5060293B2 (ja) | 2004-08-03 | 2012-10-31 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経機能におけるtaj |
EP3073267A1 (en) | 2004-09-21 | 2016-09-28 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
US7422966B2 (en) | 2005-05-05 | 2008-09-09 | Micron Technology, Inc. | Technique for passivation of germanium |
EP1891111A1 (en) | 2005-05-06 | 2008-02-27 | ZymoGenetics, Inc. | Il-31 monoclonal antibodies and methods of use |
WO2006125076A2 (en) | 2005-05-18 | 2006-11-23 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against chlamydia infection |
WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1904652A2 (en) | 2005-07-08 | 2008-04-02 | Brystol-Myers Squibb Company | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof |
RS53058B (en) | 2005-07-08 | 2014-04-30 | Biogen Idec Ma Inc. | SP35 ANTIBODIES AND THEIR APPLICATIONS |
EP1920057A4 (en) | 2005-08-03 | 2009-03-18 | Grains Res & Dev Corp | POLYSACCHARIDE synthases |
ES2526811T3 (es) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos |
US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
AU2006344395B2 (en) | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
CA2624393C (en) | 2005-11-04 | 2016-01-05 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
EA014900B1 (ru) | 2005-11-07 | 2011-02-28 | Зе Скрипс Ресеч Инститьют | Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором |
DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
EP2335733B1 (en) | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
AU2007260687B2 (en) | 2006-06-14 | 2013-12-12 | Provention Bio, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
ES2599319T3 (es) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Anticuerpos específicos de Fc RIIB y métodos de uso de éstos |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
ES2548714T3 (es) | 2006-09-01 | 2015-10-20 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y procedimientos de uso |
EP2354254A1 (en) | 2006-09-06 | 2011-08-10 | Ortho-McNeil Pharmaceutical, Inc. | Biomarkers for assessing response to C-met treatment |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
HUE036793T2 (hu) | 2007-01-09 | 2018-07-30 | Biogen Ma Inc | SP35 antitestek és alkalmazásuk |
CN101588812A (zh) | 2007-01-18 | 2009-11-25 | 默克专利有限公司 | 使用整联蛋白配体治疗癌的特异疗法和药物 |
WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
NO3072525T3 (ja) | 2007-05-14 | 2018-06-30 | ||
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
PL2182983T3 (pl) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
ES2916498T3 (es) | 2007-12-06 | 2022-07-01 | Genalyte Inc | Método para identificar una secuencia de nucleótidos en una especie desconocida de ácido nucleico; y dispositivo para llevar a cabo el método |
AU2008341050B2 (en) | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
EP2260102A1 (en) | 2008-03-25 | 2010-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
AU2009242453B2 (en) | 2008-05-02 | 2014-12-04 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
WO2009148896A2 (en) | 2008-05-29 | 2009-12-10 | Nuclea Biotechnologies, LLC | Anti-phospho-akt antibodies |
EP2982695B1 (en) | 2008-07-09 | 2019-04-03 | Biogen MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
EP3572796B8 (en) | 2008-10-27 | 2023-01-18 | Genalyte, Inc. | Biosensors based on optical probing and sensing |
JP6113404B2 (ja) | 2008-10-29 | 2017-04-12 | アブリンクス エン.ヴェー. | 単一ドメイン抗原結合分子の精製方法 |
EP4104821A1 (en) | 2008-10-29 | 2022-12-21 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP2356251A1 (en) | 2008-11-07 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
CN102438652B (zh) | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
US20120003235A1 (en) | 2008-12-31 | 2012-01-05 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US20110014190A1 (en) | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
US20110311521A1 (en) | 2009-03-06 | 2011-12-22 | Pico Caroni | Novel therapy for anxiety |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
CN102458468B (zh) | 2009-05-08 | 2018-05-18 | 瓦西尼斯公司 | 抗-cd100抗体和其使用方法 |
WO2010136168A2 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
EA023179B1 (ru) | 2009-08-13 | 2016-05-31 | Круселл Холланд Б.В. | Антитела против респираторного синцитиального вируса (pcb) и способы их применения |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
US20120244170A1 (en) | 2009-09-22 | 2012-09-27 | Rafal Ciosk | Treating cancer by modulating mex-3 |
EP2483289B1 (en) | 2009-10-02 | 2019-03-20 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
SI2486141T1 (en) | 2009-10-07 | 2018-06-29 | Macrogenics, Inc. | FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
US20130089538A1 (en) | 2010-06-10 | 2013-04-11 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
NZ603488A (en) | 2010-07-09 | 2015-02-27 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
JP2013536175A (ja) | 2010-07-16 | 2013-09-19 | アブリンクス エン.ヴェー. | 修飾された単一ドメイン抗原結合分子及びその使用 |
WO2012007137A1 (en) | 2010-07-16 | 2012-01-19 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
JP6097690B2 (ja) | 2010-09-02 | 2017-03-15 | ヴァクシネックス, インコーポレイテッド | 抗cxcl13抗体およびそれを用いる方法 |
EP2614080A1 (en) | 2010-09-10 | 2013-07-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
AU2011316917B2 (en) | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
CA2816995C (en) | 2010-11-05 | 2019-12-31 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, a body corporate and politic | Optical analyte detection systems and methods of use |
WO2012065937A1 (en) | 2010-11-15 | 2012-05-24 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Anti-fungal agents |
MX361242B (es) | 2011-03-30 | 2018-11-30 | Ablynx Nv | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. |
JP2014515753A (ja) | 2011-04-21 | 2014-07-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規な結合剤−薬物複合体(adc)およびそれらの使用 |
DK2707383T3 (en) | 2011-05-13 | 2018-07-23 | Biogen Ma Inc | PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULPHIDE BINDINGS |
ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
EP2717911A1 (en) | 2011-06-06 | 2014-04-16 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
US9221906B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of inhibiting solid tumor growth by administering GPR49 antibodies |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
DK2773671T3 (da) | 2011-11-04 | 2021-11-15 | Zymeworks Inc | Udformning af stabilt heterodimert antistof med mutationer i fc-domænet |
EP2776022A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
US20150023989A1 (en) | 2011-12-14 | 2015-01-22 | Seattle Genetics, Inc. | New antibody drug conjugates (adcs) and the use thereof |
US20140363448A1 (en) | 2012-01-02 | 2014-12-11 | Novartis Ag | Cdcp1 and breast cancer |
CN108324943B (zh) | 2012-02-10 | 2024-03-08 | 思进股份有限公司 | Cd30+癌症的检测和治疗 |
KR102090969B1 (ko) | 2012-03-02 | 2020-03-19 | 백시넥스 인코포레이티드 | B 세포-매개 염증 질환의 치료 방법 |
EP2825885B1 (en) | 2012-03-12 | 2021-05-12 | The Board of Trustees of the University of Illinois | Optical analyte detection systems with magnetic enhancement |
WO2013144240A1 (en) | 2012-03-29 | 2013-10-03 | Friedrich Miescher Institute For Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
WO2013166594A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
JP6122948B2 (ja) | 2012-05-15 | 2017-04-26 | モルフォテック, インコーポレイテッド | 胃癌の治療のための方法 |
IN2014KN02831A (ja) | 2012-05-24 | 2015-05-08 | Mountgate Group Ltd | |
WO2014001482A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
WO2014006114A1 (en) | 2012-07-05 | 2014-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
PL2888283T3 (pl) | 2012-08-24 | 2019-03-29 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
US20150376597A1 (en) | 2013-02-08 | 2015-12-31 | Friedrich Miescher Institute For Biomedical Research (Fmi) | Novel methods for the targeted introduction of viruses into cells |
WO2014137355A1 (en) | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
US9983206B2 (en) | 2013-03-15 | 2018-05-29 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enhancing immunoassays |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
EP3030902B1 (en) | 2013-08-07 | 2019-09-25 | Friedrich Miescher Institute for Biomedical Research | New screening method for the treatment friedreich's ataxia |
WO2015066027A2 (en) | 2013-10-28 | 2015-05-07 | Dots Devices, Inc. | Allergen detection |
JP6525474B2 (ja) | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラキナーゼ阻害剤と抗cd30抗体の併用 |
MX2016008013A (es) | 2013-12-23 | 2017-05-12 | Bayer Pharma AG | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. |
AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
CN106456784A (zh) | 2014-04-16 | 2017-02-22 | 拜康有限公司 | 包含摩尔过量的山梨醇的稳定蛋白质制剂 |
ES2869459T3 (es) | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
EP3154579A1 (en) | 2014-06-13 | 2017-04-19 | Friedrich Miescher Institute for Biomedical Research | New treatment against influenza virus |
AU2015280436A1 (en) | 2014-06-23 | 2017-02-02 | Bionomics, Inc. | Antibodies that bind LGR4 |
WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
US20170165261A1 (en) | 2014-07-01 | 2017-06-15 | Brian Arthur Hemmings | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
US10961298B2 (en) | 2014-08-21 | 2021-03-30 | The Government Of The United States, Represented By The Secretary Of The Army | Monoclonal antibodies for treatment of microbial infections |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
MX2017006167A (es) | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
WO2016081835A2 (en) | 2014-11-21 | 2016-05-26 | University Of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
EP3233127A1 (de) | 2014-12-15 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern |
AU2016239331C1 (en) | 2015-03-31 | 2020-01-30 | Medimmune Limited | A novel IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same |
SG11201710639YA (en) | 2015-06-22 | 2018-01-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
CN107921145A (zh) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物(adc) |
JP6905941B2 (ja) | 2015-06-23 | 2021-07-21 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体 |
WO2017031353A1 (en) | 2015-08-19 | 2017-02-23 | Rutgers, The State University Of New Jersey | Novel methods of generating antibodies |
KR20180042449A (ko) | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T 세포 수용체(tcr) 결합 항체 및 이의 용도 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
US20180348224A1 (en) | 2015-10-28 | 2018-12-06 | Friedrich Miescher Institute For Biomedical Resear Ch | Tenascin-w and biliary tract cancers |
MX2018005061A (es) | 2015-11-12 | 2019-02-28 | Siamab Therapeutics Inc | Compuestos de interacción con glicanos y métodos de uso. |
AU2017239038B2 (en) | 2016-03-22 | 2024-06-27 | Bionomics Inc | Administration of an anti-LGR5 monoclonal antibody |
SG10202008909VA (en) | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
JP7161266B2 (ja) | 2016-08-05 | 2022-10-26 | メディミューン,エルエルシー | 抗o2抗体およびその使用 |
AU2017326751A1 (en) | 2016-09-16 | 2019-03-14 | Bionomics Limited | Antibody and checkpoint inhibitor combination therapy |
SG11201903063UA (en) | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
KR102603681B1 (ko) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | 항체 및 이의 사용방법 |
JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
US20190351066A1 (en) | 2016-12-21 | 2019-11-21 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
MX2019010202A (es) | 2017-03-03 | 2019-10-02 | Seattle Genetics Inc | Compuestos que interactuan con glicano y metodos de uso. |
CN110799529A (zh) | 2017-04-22 | 2020-02-14 | 免疫治疗有限公司 | 改良lamp构建物 |
IL297073B2 (en) | 2017-05-02 | 2023-12-01 | Immunomic Therapeutics Inc | LAMP constructs containing cancer antigens |
KR102344616B1 (ko) | 2017-05-30 | 2021-12-31 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 항-더블코르틴-유사 키나제 1 항체 및 사용 방법 |
KR102324568B1 (ko) | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120 및 CD3을 표적화하는 다중특이적 항체 |
EP3668969A1 (en) | 2017-08-18 | 2020-06-24 | Friedrich Miescher Institute for Biomedical Research | Novel methods for the targeted introduction of viruses into cells and tissues |
BR112020006892A2 (pt) | 2017-10-11 | 2020-10-06 | Seattle Genetics, Inc. | métodos de reduzir efeitos colaterais de terapia de conjugado anticorpo anti-cd30 fármaco |
JP2021501800A (ja) | 2017-11-01 | 2021-01-21 | シアトル ジェネティクス,インコーポレイティド | 抗cd30抗体薬物複合体療法の副作用を軽減する方法 |
EP3706795A4 (en) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES |
US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
BR112020018948A2 (pt) | 2018-03-23 | 2021-01-05 | Seattle Genetics, Inc. | Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido |
JP2021521273A (ja) | 2018-04-12 | 2021-08-26 | メディアファーマ エス.アール.エル. | Lgals3bp抗体−薬剤結合体及びがん治療のためのその使用 |
KR20210044183A (ko) | 2018-05-07 | 2021-04-22 | 젠맵 에이/에스 | 항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 |
MX2020011176A (es) | 2018-05-07 | 2020-11-12 | Genmab As | Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento. |
JP2021523185A (ja) | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | アレルゲンを含む改善されたlamp構築物 |
EA202190059A1 (ru) | 2018-06-18 | 2021-04-21 | Байер Акциенгезельшафт | Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности |
CA3102859A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
CA3114922A1 (en) | 2018-10-01 | 2020-04-09 | Seagen Inc. | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
WO2020092210A1 (en) | 2018-10-30 | 2020-05-07 | Genmab A/S | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
AU2020219732A1 (en) | 2019-02-05 | 2021-08-05 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
CN113874392A (zh) | 2019-03-28 | 2021-12-31 | 丹尼斯科美国公司 | 工程化抗体 |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
CN114867751A (zh) | 2019-08-12 | 2022-08-05 | 阿帕特夫研究和发展有限公司 | 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体 |
US20220347313A1 (en) | 2019-09-25 | 2022-11-03 | Seagen, Inc. | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers |
CA3155634A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Anti-pd-l1 antibodies and antibody-drug conjugates |
WO2021077051A1 (en) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
KR20220121792A (ko) | 2019-11-04 | 2022-09-01 | 씨젠 인크. | 항-cd30 항체-약물 컨쥬게이트 및 hiv 감염 치료를 위한 이의 용도 |
EP4055051A1 (en) | 2019-11-07 | 2022-09-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法 |
TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗-cd70抗體治療癌症之方法 |
US20230090868A1 (en) | 2020-01-31 | 2023-03-23 | Seagen Inc. | Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma |
JP2023526236A (ja) | 2020-05-13 | 2023-06-21 | シージェン インコーポレイテッド | 抗cd30抗体-薬物コンジュゲートの組合せを使用する、がんを処置する方法 |
CA3189225A1 (en) | 2020-08-04 | 2022-02-10 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
CA3192526A1 (en) | 2020-09-04 | 2022-03-10 | Rutgers, The State University Of New Jersey | Sars-cov-2 vaccines and antibodies |
WO2022081436A1 (en) | 2020-10-15 | 2022-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
CA3200671A1 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
JP2023551907A (ja) | 2020-12-01 | 2023-12-13 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 腫瘍関連抗原及びcd3結合タンパク質、関連する組成物、及び方法 |
AU2022207708A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
EP4277665A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
WO2022251446A1 (en) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
CA3218481A1 (en) | 2021-06-14 | 2022-12-22 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
WO2023278377A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
IL311771A (en) | 2021-10-06 | 2024-05-01 | BioNTech SE | Multispecific binding agents against PD-L1 and CD137 in combination |
IL312110A (en) | 2021-10-29 | 2024-06-01 | Seagen Inc | Cancer treatment methods with a combination of anti-PD-1 antibody and antibody-CD30 conjugate |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023192436A1 (en) | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
WO2024054436A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2024097816A1 (en) | 2022-11-03 | 2024-05-10 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
WO2024105205A1 (en) | 2022-11-17 | 2024-05-23 | Bayer Aktiengesellschaft | Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups |
US20240226313A1 (en) | 2022-11-17 | 2024-07-11 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8610983D0 (en) * | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
DE3850542T2 (de) * | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
WO1991000360A1 (en) * | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
-
1991
- 1991-10-04 JP JP51827991A patent/JP3583420B2/ja not_active Expired - Fee Related
- 1991-10-04 AU AU88694/91A patent/AU667460B2/en not_active Ceased
- 1991-10-04 WO PCT/US1991/007283 patent/WO1992005793A1/en active IP Right Grant
- 1991-10-04 CA CA002093022A patent/CA2093022C/en not_active Expired - Fee Related
- 1991-10-04 DE DE69130709T patent/DE69130709T3/de not_active Expired - Fee Related
- 1991-10-04 EP EP91919595A patent/EP0553244B8/en not_active Expired - Lifetime
- 1991-10-04 DK DK91919595T patent/DK0553244T4/da active
- 1991-10-04 ES ES91919595T patent/ES2129029T5/es not_active Expired - Lifetime
- 1991-10-04 AT AT91919595T patent/ATE175118T1/de not_active IP Right Cessation
-
1999
- 1999-03-30 GR GR990400921T patent/GR3029830T3/el unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002502802A (ja) * | 1997-12-02 | 2002-01-29 | ニューララブ リミテッド | アミロイド形成疾患の予防および処置 |
JP2006131639A (ja) * | 1997-12-02 | 2006-05-25 | Neuralab Ltd | アミロイド形成疾患の予防および治療剤 |
JP4677333B2 (ja) * | 1997-12-02 | 2011-04-27 | ヤンセン アルツハイマー イミュノセラピー | アミロイド形成疾患の予防および治療剤 |
Also Published As
Publication number | Publication date |
---|---|
ES2129029T5 (es) | 2005-10-16 |
EP0553244B2 (en) | 2005-04-06 |
WO1992005793A1 (en) | 1992-04-16 |
DE69130709D1 (de) | 1999-02-11 |
AU667460B2 (en) | 1996-03-28 |
DK0553244T3 (da) | 1999-08-30 |
AU8869491A (en) | 1992-04-28 |
EP0553244A4 (ja) | 1994-02-09 |
GR3029830T3 (en) | 1999-06-30 |
ES2129029T3 (es) | 1999-06-01 |
EP0553244B8 (en) | 2005-06-08 |
ATE175118T1 (de) | 1999-01-15 |
JP3583420B2 (ja) | 2004-11-04 |
CA2093022C (en) | 2005-02-22 |
DE69130709T3 (de) | 2005-12-22 |
EP0553244B1 (en) | 1998-12-30 |
EP0553244A1 (en) | 1993-08-04 |
DK0553244T4 (da) | 2005-08-01 |
DE69130709T2 (de) | 1999-07-22 |
CA2093022A1 (en) | 1992-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3583420B2 (ja) | 二特異的試薬を用いた標的免疫化 | |
US6248332B1 (en) | Targeted immunostimulation with bispecific reagents | |
US6197298B1 (en) | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals | |
EP0136835B1 (en) | Process for the preparation of antibody compositions of therapeutic agents having an extended serum half-life | |
US6117982A (en) | Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators | |
US6129916A (en) | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates | |
US8444974B2 (en) | Use of antibodies for the vaccination against cancer | |
JP4212111B2 (ja) | 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体 | |
JPH0674210B2 (ja) | 抗原の免疫原性の増強 | |
JP2000505091A (ja) | 抗―Fcαレセプター抗体からなる治療用多重特異的化合物 | |
JPH05504554A (ja) | 免疫強化を促進するための方法と組成物 | |
JPH05505595A (ja) | 二つのエフェクター機能を有する二元特異性異種抗体 | |
JPH05504677A (ja) | IgAレセプターに特異的なモノクロナール抗体 | |
JPH11509558A (ja) | 免疫反応を惹起するための、多数エピトープ含有抗原の再構成法および組成物 | |
US6656481B1 (en) | Vaccinal preparations | |
US6106835A (en) | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators | |
JPH0222236A (ja) | 感作されたエフェクター細胞を腫瘍部位に向けるためのシグナルとしてのモノクローナル抗体及びその接合体の使用 | |
WO2001032207A1 (en) | Methods for conferring active/passive immunotherapy | |
Sivolapenko et al. | Enhanced in vivo immunogenicity induced by an antibody to the IL‐4 receptor‐associated gp200‐MR6 molecule | |
EP0467416A1 (en) | Antibody compositions of therapeutic agents having an extended serum half-life | |
US20040265318A1 (en) | Use of antibodies for the vaccination against cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040507 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040706 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040729 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080806 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |